It has been proposed that the downregulation of the WNK-SPAK/OSR1 signaling cascade may work as a therapeutic strategy in disorders of altered inhibition, such as epilepsy, schizophrenia, and autism spectrum disorders (Kahle and Delpire, 2016; Côme et al., 2019). Here, STK39 is linked to autism spectrum disorder.